Due to this heterogeneity, the treatment of neuroblastoma is based on each patient’s risk of relapse and death, which is stratified into low, intermediate, and high using specific criteria alone or in combination, including age, MYCN oncogene amplification, metastatic disease, and histology/pathology [4]. Here, MYCN is linked to neuroblastoma.